Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mebufotenin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 6/20 | 0.85 |
| ▸ | HTR1B | P28222 | 5/20 | 0.85 |
| ▸ | HTR1A | P08908 | 4/20 | 0.85 |
| ▸ | HTR6 | P50406 | 3/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.85 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.85 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.85 |
| ▸ | HTR3B | O95264 | 1/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.85 |
| ▸ | HTR2A | P28223 | 1/20 | 0.85 |
| ▸ | HTR2C | P28335 | 1/20 | 0.85 |
| ▸ | HTR1E | P28566 | 1/20 | 0.85 |
| ▸ | HTR1F | P30939 | 1/20 | 0.85 |
| ▸ | HTR7 | P34969 | 1/20 | 0.85 |
| ▸ | HTR2B | P41595 | 1/20 | 0.85 |
| ▸ | HTR3A | P46098 | 1/20 | 0.85 |
| ▸ | HTR5A | P47898 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL8869617 | 0.93 | KMT2A (0.87) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL29351950 | 0.92 | HTR1D (1.00) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL27221706 | 0.92 | HTR1D (1.00) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL31098269 | 0.92 | HTR1D (1.00) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL132733 | 0.92 | HTR1D (1.00) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL23927938 | 0.92 | KMT2A (0.84) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL30199593 | 0.92 | KMT2A (0.84) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL26111484 | 0.91 | HTR1D (0.97) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL25330504 | 0.91 | HTR1D (0.97) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL25329816 | 0.90 | KMT2A (0.81) | KMT2AHTR1DHTR1BHTR1AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050226-A1 | Dopamine analog amide | SHASHOUA VICTOR E (US) | 2003-03-13 | — | — | US | disclosed |
| US-6407137-B2 | A PRODRUG COMPOUND CAPABLE OF FACILITATING THE PASSAGE OF A DRUG ACROSS THE BLOOD BRAIN BARRIER COMPRISING A FATTY ACID COUPLED TO A DRUG TO FORM A PRODRUG | PROTARGA, INC. | 2002-06-18 | — | — | US | disclosed |
| US-20010056116-A1 | Dopamine analog amide | LUITPOLD PHARMACEUTICALS, INC. | 2001-12-27 | — | — | US | disclosed |
| US-6258836-B1 | FATTY ACID COUPLED TO ANTIAIDS SUBSTANCE, ANTIBIOTIC, CHOLINERGIC AGONIST AND OTHER USES FOR PASSING THE BLOOD BRAIN BARRIER | PROTARGA, INC. | 2001-07-10 | — | — | US | disclosed |
| US-6107499-A | FACILITATING THE TRANSPORT OF A NEUROTRANSMITTER ACROSS THE BLOOD BRAIN BARRIER BY ADMINISTERING THE DRUG, A NEUROTRANSMITTER SUCH AS DOPAMINE COVALENTLY COUPLED TO A SINGLE, STRAIGHT-CHAINED FATTY ACID CARRIER MOLECULE | NEUROMEDICA, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| US-5994392-A | PASSAGE OF DRUG THROUGH BLOOD BRAIN BARRIER | NEUROMEDICA, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| EP-0871731-A2 | ANTIBODIES FOR THE CONTROL OF CYST NEMATODES AND TRANSGENIC PLANTS EXPRESSING THEM | Landbouwuniversiteit Wageningen (NL) | 1998-10-21 | — | — | EP | disclosed |
| WO-1996022372-A2 | ANTIBODIES FOR THE CONTROL OF CYST NEMATODES AND TRANSGENIC PLANTS EXPRESSING THEM | LANDBOUWUNIVERSITEIT WAGENINGEN (NL) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056116-A1 | Dopamine analog amide | FABP7, SLC6A3, ALOX15 | SLC6A4 68/4885KMT2A 1312/4885HTR1D 214/4885 |
| US-20030050226-A1 | Dopamine analog amide | FABP7, SLC6A3, ALOX15 | SLC6A4 68/4885KMT2A 1312/4885HTR1D 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.